Immunovant Inc. (IMVT)
Immunovant Inc. (IMVT) Stock Price, Analysis & Data
| Bid | 31.5 |
| Market Cap | 9.03B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -538.22M |
| Beta | 0.81 |
| EPS (ttm) | -2.94 |
| PE Ratio (ttm) | n/a |
| Forward PE | -17.49 |
| P/B (ttm) | 12.26 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 9, 2026 |
| Ask | 53.22 |
| Volume | 1,215,558 |
| Avg. Volume (20D) | 1,712,872 |
| Open | 41.72 |
| Previous Close | 41.82 |
| Day's Range | 41.46 - 43.89 |
| 52-Week Range | 14.47 - 43.89 |
| Analyst | Buy |
| Price Target | 48.5 (10.96%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IMVT
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018...
Financial Performance
In 2026, Immunovant's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -505.61M, an increase of 22.17%.
Financial StatementsAnalyst Forecast
According to 16 analyst ratings, the average rating for IMVT stock is "Buy". The 12-month stock price forecast is 48.5, which is upside of 10.96% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
